Introduction {#Sec1}
============

Fungal eye infections are rare but can result in keratitis \[[@CR1], [@CR2]\] and even endophthalmitis. Many different types of fungi can cause eye infections, but the most common infections are caused by species of*Fusarium*,*Aspergillus*,*Curvularia*, and *Candida*. Trauma is the most frequent predisposing factor, although important contributors include ocular and systemic defects along with the prior application of corticosteroids \[[@CR3]\]. Endophytic fungi are ubiquitous organisms found in plants. They usually reside intercellularly or intracellularly without causing any apparent symptoms of infection, while all plants are known to harbor endophytes \[[@CR4]\]. *Phoma* is a genus of endophytic fungus which may also appear on plant foliage. In contrast to most fungal species that can cause eye infections, the involvement of any *Phoma* sp. in eye injury is previously unreported. In fact, *Phoma* sp. infection appears to be very rare: among 209 references retrieved in a search in PubMed (lemma: *Phoma* sp.; last accessed on September 19, 2019), only eight refer (mostly tangentially) to human infection \[[@CR5]--[@CR12]\] (mainly in immunocompromised hosts \[[@CR8], [@CR12]\]), and only one of those may be said to remotely implicate a *Phoma* sp. in eye infection \[[@CR5]\]! Herein, we present a unique case of persistent corneal infection by a *Phoma* sp. in an immunocompetent adult with no clear origin of infection.

Case (Summary in Table [1](#Tab1){ref-type="table"}) {#Sec2}
====================================================

A 47-year-old female who was a long-time soft contact lens user and was meticulous with her lens hygiene presented to her ophthalmologist (March 2014) following a month of constant tearing and progressively worsening blurred vision in the right eye. Anamnesis indicated a preoccupation with gardening and the recent use of commercially available prepackaged plant seeds. The initial diagnosis was bacterial keratitis. She was referred to our center on June 4, 2014 due to a persistent infectious corneal ulcer with a central corneal ulcerative area (0.75 mm × 1 mm), mild stromal infiltration, and a reduced best-corrected visual acuity of 0.3. We interrupted topical treatment for 48 h to obtain culture material (corneal scrapings) and determine the causative agent and her sensitivity to antibiotics. We subsequently initiated treatment (coll. moxifloxacin, coll. azithromycin, washing with Betadine 5%) according to our standard therapy protocol.Table 1Timeline of the caseFebruary 2014Initial symptoms appearMarch 2014Visit to ophthalmologistJune 4, 2014Referral to Ophthalmica; persistent infectious corneal ulcer with a central corneal ulcerative area (0.75 mm × 1 mm), mild stromal infiltration, VA: 3/10June 6, 2014Corneal scrapings obtained (*Staphylococcus epidermidis*); coll. moxifloxacin, coll. azithromycin, washing with Betadine 5%June 24, 2014Lunate extension of the infiltration; biopsy of its limits (*Phoma* sp.)July 8, 2014Coll. gentamicin, coll. vancomycinJuly 30, 2014Incomplete healing inferiorly with fibrosisAugust 9, 2014Central melting; sealed descemetocele with tectonic graftSeptember 10, 2014New lunate extension at superior border of the tectonic graft; biopsy of its limits (*Phoma* sp.); ketoconazole 200 mg b.i.d. systemically and topical application of fluconazole hourlySeptember 15, 2014Hypopyon (1.5 mm) with paracentral ulceration and melting adjacent to the graftOctober 5, 2014Enlarged whitish infiltrate at superior border of the graft and paracentral melting; topical amphotericin 0.015% hourly and intrastromal injections of amphotericinOctober 15, 2014Tectonic 7.5 mm diameter full-thickness keratoplasty, anterior chamber washing and intrastromal injection of amphotericin B at the graft edges; corneal biopsy (*Phoma foliaceiphila*)\~ November 7, 2014Susceptibility results: susceptible to amphotericin B, itraconazole, voriconazole, posaconazole, and micafungin; resistant to flucytosine and caspofungin; voriconazole 400 mg, s: 1 × 2November 21, 2014Small suture infiltration appears; immediate suture removal and intrastromal injectionDecember 19, 2014Infiltration has invaded the graft and enlarged, despite continuing systemic voriconazole administrationDecember 25, 2014 to January 1, 2015Infiltrate has developed central melting with hypopyon and perforationJanuary 2, 2015Second graft. Reconstruction of anterior chamber, removal of crystalline lens, anterior segment wash-on and core (open sky) vitrectomy, with removal of retroiridic inflammatory membranes and injection of combination of amphotericin-voriconazole into the vitreal cavity; systemic treatment with voriconazole (200 mg b.i.d.) and posaconazole started, initially for three monthsMarch 16, 2015Clear graft; diminished peripheral neovascularization. Best-corrected VA: 5/10June 10, 2015Discontinued systemic voriconazoleJuly 1, 2015Infiltrate arising from the posterior surface of the irisJuly 2, 2015Panophthalmitis with hypopyon and posterior vitritisJuly 5, 2015Emergency PP vitrectomy and silicon oil; restarted systemic voriconazoleAugust 2016Discontinued systemic voriconazoleJanuary 2017Infection is under control

Culture demonstrated the presence of *Staphylococcus epidermidis* only, while the clinical picture kept worsening. A satellite extension of the infiltration appeared. On June 24, 2014, we biopsied the limits of the infiltration, and local therapy was changed to coll. gentamicin and coll. vancomycin on July 8, 2014 (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Right cornea with the initial infiltration and the added lunate infiltration 20 days later. The central corneal ulcer with the stromal infiltration and hypopyon are clearly seen

By July 31, 2014, incomplete healing inferiorly with fibrosis was evident. However, central melting ensued, and we sealed the descemetocele with a tectonic graft on August 9, 2014.

Microscopy (under KOH 15%) of the June 24, 2014 biopsy material revealed abundant narrow and septate fungal hyphae with an acute angle branching pattern. Specimens were inoculated on Sabouraud's dextrose agar with chloramphenicol (0.05%), malt extract agar, and Czapek--Dox agar at 30 °C and 35 °C, respectively. Following incubation (3--5 days), fungal growth (mold) was present in all cultures, with wrinkled colonies grayish to lightly tanned or light salmon-pink in color that grew at a moderately rapid pace. The mold grew at both 30 °C and 35 °C but not at 40 °C. Dark pycnidia with apical openings, abundant small fusiform conidia, and chlamydospores were present. The phenotype was identified as a *Phoma* sp.

By September 10, 2014, a second lunate extension appeared from the superior border of the tectonic graft. We again biopsied the borders of the new infiltrate, and mycology culture confirmed the previous phenotypic identification, while sequencing of the internal transcribed spacer (ITS1 and ITS2) regions of the isolate's ribosomal DNA presented the highest homology with *Phoma foliaceiphila*.

As susceptibility testing was not yet complete, we started treatment with ketoconazole 200 mg b.i.d. systemically and topical application of fluconazole hourly. By 15 Sept 2014, hypopyon developed (1.5 mm height) with paracentral ulceration and melting adjacent to the graft (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Appearance of the treated ulcer

By October 5, 2014, despite antifungal treatment, the whitish infiltrate at the superior border of the graft had enlarged, and there was paracentral melting. We changed treatment to topical amphotericin 0.015% hourly and to intrastromal injections of amphotericin in order to overcome the limited permeability of the intact epithelium.

On October 15, 2014, we proceeded with a tectonic 7.5 mm diameter full-thickness keratoplasty, anterior chamber washing, and intrastromal injection of amphotericin B at the graft edges. Additionally, we performed a corneal biopsy and sent specimens to facilitate the identification of the fungus.

Susceptibility results became available on November 7, 2014, which showed in vitro susceptibility to amphotericin B, itraconazole, voriconazole, posaconazole, and micafungin, and resistance to flucytosine and caspofungin. We changed treatment to voriconazole 400 mg, twice daily systemically.

The graft remained clear for 2 months with no clinical signs of infection. However, by November 21, 2014, a small suture infiltration had appeared, which had invaded the graft and enlarged by December 19, 2014 despite systemic voriconazole administration, immediate suture removal, and intrastromal injection.

Between December 25, 2014 and January 1, 2015, the infiltrate developed central melting with hypopyon, and perforation occurred. At this point, a dilemma arose as to whether we should perform enucleation, given the risk of dissemination of the fungal infection to the brain. We decided against it. On January 2, 2015, we proceeded with a second graft, despite the active, uncontrolled infection. We reconstructed the anterior chamber, removed the crystalline lens, and performed anterior segment wash-on and core (open sky) vitrectomy, with the removal of retroiridic inflammatory membranes and the injection of a combination of amphotericin-voriconazole into the vitreal cavity. Systemic treatment with voriconazole (200 mg b.i.d.) and posaconazole was initiated for an initial period of 3 months, and biweekly liver and kidney function tests were ordered.

By March 15, 2015, the graft remained clear while peripheral neovascularization diminished following two subconjunctival injections of steroid and bevacizumab. Best-corrected VA improved to 0.5.

On June 10, 2015, we discontinued systemic voriconazole. However, on July 1, 2015, an infiltrate arose from the posterior surface of the iris. By July 2, 2015, panophthalmitis had developed with hypopyon and posterior vitritis, in spite of a clear graft. Consequently, on July 5, 2015, we proceeded with emergency pars plana (PP) vitrectomy and silicon oil. We also restarted systemic voriconazole administration.

As of January 2017, the infection is under control. Systemic voriconazole was discontinued 14 months after the last operation (vitrectomy), and silicone oil gradually filled the anterior chamber, damaging the endothelium. This case is reported with the informed consent of the patient.

Discussion {#Sec3}
==========

Based on the literature reported in PubMed, human *Phoma* ssp. infections are extremely rare, and those reported in the literature involve the lung interstitium \[[@CR6]\], the exposed skin of farmers \[[@CR7], [@CR10]\], or immunocompromised patients \[[@CR8], [@CR11]\]. In addition, in the two cases where the investigation determined (either empirically \[[@CR7]\] or through culturing \[[@CR8]\]) a *Phoma* ssp., antibiotic susceptibility pointed to the same basic treatment options: itraconazole, ketoconazole, and amphotericin B \[[@CR7], [@CR8]\]. Fluconazole may sometimes be effective \[[@CR7]\], although a *Phoma* ssp. has been reported to be resistant to both fluconazole as well as 5-flucytosine \[[@CR8]\]. It should also be noted that targeted delivery of voriconazole by intrastromal corneal injection is considered a safe and highly effective way to treat deep recalcitrant fungal keratitis \[[@CR12]\].

A prominent feature of our case was the apparent low susceptibility of the *Phoma* sp. to antibiotic/antifungal treatment. However, *Phoma* ssp. isolated from different medicinal plants has been reported to be a promising source of antimicrobial compounds \[[@CR13]\]. This could explain the low susceptibility of the *Phoma* sp. in our case, as it is reasonable to expect that it must have evolved resistance to its own antibiotic products and related compounds.

We have not been able to determine our patient's infection route. However, the occurrence of major fungi varies with season or with leaf age. The occurrence of *Phoma* ssp. has been reported to be strongly correlated with season, reaching its maximum---in at least one meticulously investigated case---between the months of February and May \[[@CR14]\]. Although this provides only a circumstantial indication, our patient's anamnesis indicated that her infection correlated well with the seasonal peak in *Phoma* sp. occurrence!

**Enhanced digital features** To view enhanced digital features for this article go to: 10.6084/m9.figshare.7588373.
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